Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Primary Care

Journal Scan / Research · April 06, 2022

Efficacy of Amisulpride Plus Olanzepine vs Each Monotherapy in Acutely Ill Patients With Schizophrenia

The Lancet Psychiatry


Additional Info

The Lancet Psychiatry
Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial
Lancet Psychiatry 2022 Apr 01;9(4)291-306, C Schmidt-Kraepelin, S Feyerabend, C Engelke, M Riesbeck, E Meisenzahl-Lechner, PE Verde, CU Correll, M Kluge, C Makiol, A Neff, C Lange, S Englisch, M Zink, B Langguth, TB Poeppl, D Reske, E Gouzoulis-Mayfrank, G Gründer, A Hasan, A Brockhaus-Dumke, M Jäger, J Baumgärtner, S Leucht, J Cordes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading